{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:02:08Z","timestamp":1791158528986,"version":"4.1.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Current guidelines for advanced non-small cell lung cancer (NSCLC) recommend the use of targeted agents for specific driver genes after confirming genetic alterations. Although epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement are usually mutually exclusive, EGFR and ALK co-alterations have been reported increasingly in cases of NSCLC. However, the optimal treatment for these cases has not been established.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>This case series describes three patients diagnosed with advanced non-squamous NSCLC who harbored EGFR and ALK co-alterations. The complaints for each case are as follows: 57-year-old woman with coughing and dyspnea in case 1, 32-year-old man with diplopia in case 2 and 77-year-old woman with chest discomfort in case 3.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Three never-smokers were diagnosed pathologically with stage IV adenocarcinoma of the lung. Subsequent molecular studies revealed the EGFR L858R mutation gene and ALK rearrangement, which were proven by real-time polymerase chain reaction and fluorescence in situ hybridization, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>All 3 patients received first-line therapy with EGFR-tyrosine kinase inhibitors (TKIs). Cases 1 and 2 were treated with ALK-TKIs as second-line therapy and received additional EGFR-TKIs as third- and fourth-line regimens.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patients achieved partial responses to EGFR-TKIs according to radiologic findings. However, second-line ALK-TKI therapy was ineffective in cases 1 and 2.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Cases of NSCLC with concomitant EGFR mutation and ALK rearrangement are rare, and the selection of an optimal targeted therapy is challenging. Here, EGFR-TKI appeared to yield better outcomes than ALK-TKI in patients with NSCLC who harbored EGFR\/ALK co-alterations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000014699","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T20:42:28Z","timestamp":1551386548000},"page":"e14699","source":"Crossref","is-referenced-by-count":10,"title":["Co-alteration of EGFR mutation and ALK rearrangement in non-small cell lung cancer"],"prefix":"10.1097","volume":"98","author":[{"given":"Hong-Joon","family":"Shin","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Chonnam National University Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo Gun","family":"Kho","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chonnam National University Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Seok","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chonnam National University Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha Young","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chonnam National University Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Ok","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chonnam National University Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Il","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chonnam National University Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Chul","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chonnam National University Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheol-Kyu","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chonnam National University Medical School"},{"name":"Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital, Jeonnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Chul","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chonnam National University Medical School"},{"name":"Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital, Jeonnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo-Duk","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chonnam National University Medical School"},{"name":"Department of Pathology, Chonnam National University Medical School, Gwangju, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Jae","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chonnam National University Medical School"},{"name":"Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital, Jeonnam"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4046\/trd.2016.79.2.58","article-title":"Epidemiology of lung cancer in Korea: recent trends","volume":"79","author":"Park","year":"2016","journal-title":"Tuberc Respir Dis"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4068\/cmj.2018.54.2.90","article-title":"Updates on cancer epidemiology in Korea, 2018","volume":"54","author":"Kweon","year":"2018","journal-title":"Chonnam Med J"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S1470-2045(09)70110-X","article-title":"EGFR testing in lung cancer is ready for prime time","volume":"10","author":"Hirsch","year":"2009","journal-title":"Lancet Oncol"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"59889","DOI":"10.18632\/oncotarget.17431","article-title":"Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases","volume":"8","author":"Lo Russo","year":"2017","journal-title":"Oncotarget"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.2147\/OTT.S133349","article-title":"ALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma","volume":"10","author":"Mao","year":"2017","journal-title":"Onco Targets Ther"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jtho.2016.12.003","article-title":"Clinical outcome of ALK-positive non-small cell lung cancer (NSCLC) patients with de novo EGFR or KRAS co-mutations receiving tyrosine kinase inhibitors (TKIs)","volume":"12","author":"Schmid","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.cllc.2015.11.004","article-title":"Non-small-cell lung cancer patients who carry a double mutation of EGFR, EML4-ALK or KRAS: frequency, clinical-pathological characteristics, and response to therapy","volume":"17","author":"Ulivi","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1158\/1078-0432.CCR-13-0699","article-title":"Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation","volume":"20","author":"Yang","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.2147\/OTT.S121923","article-title":"Effective treatment with icotinib in lung adenocarcinoma with EGFR and ALK co-alterations and brain metastasis","volume":"9","author":"Ye","year":"2016","journal-title":"Onco Targets Ther"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.2169\/internalmedicine.0383-17","article-title":"Pulmonary adenocarcinoma, harboring both an EGFR mutation and ALK rearrangement, presenting a stable disease to erlotinib and a partial response to alectinib: a case report","volume":"57","author":"Yokoyama","year":"2018","journal-title":"Intern Med"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J Clin Oncol"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1200\/JCO.2015.64.2322","article-title":"Prospective analysis of oncogenic driver mutations and environmental factors: Japan molecular epidemiology for lung cancer study","volume":"34","author":"Kawaguchi","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201903010-00046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T18:33:47Z","timestamp":1694716427000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201903010-00046"}},"subtitle":["Case series"],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000014699","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}